NATIONAL MARROW DONOR PROGRAM
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1986-01-01
- Employees
- 996
- Market Cap
- -
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation
- Conditions
- LeukemiaLymphomaMyelodysplastic Syndromes
- First Posted Date
- 2008-08-19
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- National Marrow Donor Program
- Target Recruit Count
- 3621
- Registration Number
- NCT00737516
- Locations
- 🇺🇸
StemCyte International Cord Blood Center, Covina, California, United States
🇺🇸Children's Hospital of Orange County Cord Blood Bank, Orange, California, United States
🇺🇸Ashley Ross Cord Blood Program, San Diego, California, United States
News
Experts Call for Ecosystem-Wide Approach to Address Disparities in Stem Cell Therapy Access
Leading experts at the 2025 Transplant and Cellular Therapy Meetings emphasize the critical need to address social vulnerabilities affecting patient access to stem cell transplants and CAR T-cell therapies.
ACCESS Trial Shows Promising Survival Rates with PTCy GVHD Prophylaxis in HLA-Mismatched Transplants
Phase 2 ACCESS trial demonstrates 84% one-year overall survival rate using post-transplant cyclophosphamide for GVHD prevention in HLA-mismatched unrelated donor transplants.
CAST Regimen Improves Outcomes in Half-Matched Stem Cell Transplants
A new CAST regimen, combining post-transplant cyclophosphamide, abatacept, and tacrolimus, shows promise in preventing graft-versus-host disease (GVHD) after haploidentical hematopoietic stem cell transplantation (HSCT).